Cura Sen Therapeutics
Biotechnology, 930 Brittan Ave, San Carlos, California, 94070, United States, 11-50 Employees
Phone Number: +16*********
Who is CURASEN THERAPEUTICS
Its time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraS...
Read More
-
Headquarters: 930 Brittan Ave, San Carlos, California, 94070, United States
-
Date Founded: 2017
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from CURASEN THERAPEUTICS
CuraSen Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CuraSen Therapeutics
Answer: CuraSen Therapeutics's headquarters are located at 930 Brittan Ave, San Carlos, California, 94070, United States
Answer: CuraSen Therapeutics's phone number is +16*********
Answer: CuraSen Therapeutics's official website is https://curasen.com
Answer: CuraSen Therapeutics's revenue is $5 Million to $10 Million
Answer: CuraSen Therapeutics's SIC: 2836
Answer: CuraSen Therapeutics's NAICS: 541714
Answer: CuraSen Therapeutics has 11-50 employees
Answer: CuraSen Therapeutics is in Biotechnology
Answer: CuraSen Therapeutics contact info: Phone number: +16********* Website: https://curasen.com
Answer: Its time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinsons disease and Alzheimers disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseasesand advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases perhaps the hypocenter of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation JJDC, Inc. (JJDC), and Pappas Capital.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month